Eric W. Linsley is Managing General Partner of BioInnovation Capital. Eric oversees fund activities, runs the North Carolina lab, and focuses on opportunities in therapeutics, laboratory tools, diagnostics, and devices. He has a long history of early stage life sciences investment success, most recently at Pappas Ventures in Durham, NC. Prior to joining Pappas Ventures in 2000, Eric served as Chief Financial Officer of TriPath Imaging, Inc. (Nasdaq: TPTH), a medical device company in the Ampersand Ventures portfolio, which was acquired in 2006 by Becton Dickinson. Eric played a key role in facilitating the three-way merger between AutoCyte, NeoPath and Neuromedical Systems to form TriPath in 1999. Prior to the formation of TriPath, he was CFO of AutoCyte, one of the TriPath predecessors, which completed a successful public stock offering in 1997.At Pappas Ventures, Eric served on the Board of Panacos Pharmaceuticals (Nasdaq: PANC) and played a key role in its successful reverse merger with a publicly-traded company. He was directly responsible for investments in Peninsula Pharmaceuticals (acquired by Johnson & Johnson in 2005), and Cerexa (acquired by Forest Laboratories in 2007). Other representative investments included Balance Therapeutics, Envisia, FlowCardia (sold to BARD), LipoScience (Nasdaq: LPDX), Liquidia (Nasdaq: LQDA), Milestone Pharmaceuticals, Nuvasive (Nasdaq: NUVA) and Ultragenyx (Nasdaq: RARE). Eric’s team at Pappas Ventures also invested in Achillion (Nasdaq: ACHN), Chimerix, (Nasdaq: CMRX), Lumena (sold to Shire), Plexxikon (sold to Daiichi Sankyo), Rotation Medical (sold to Smith & Nephew), Tesaro (Nasdaq: TSRO), and TyRx (sold to Medtronic).
Listed skills include Venture Capital, Start Ups, Mergers And Acquisitions, Corporate Development, and 30 others.
